Topotecan appears to be relatively unaffected by the most common multidrug resistance mechanisms, may potentiate cytotoxicity of alkylators, has good penetration into the central nervous system, is active against a variety of neoplasms, and has myelosuppression as its paramount toxicity. We present our experience with a myeloablative regimen that includes topotecan. Twenty-one patients with poor-prognosis tumors and intact function of key organs received topotecan 2 mg/m 2 by 30-min intravenous (i.v.) infusion on days −8, −7, −6, −5, −4; thiotepa 300 mg/m 2 by 3 h i.v. infusion on days −8, −7, −6; and carboplatin by 4 h i.v. infusion on days −5, −4, −3 with a daily dose derived from the pediatric Calvert formula, using a targeted area under the curve of seven mg/ml* min (ෂ500 mg/m 2 /day). Stem cell rescue was on day 0. The patients were 1 to 29 (median 4) years old; 18 were in complete remission (CR) and three in partial remission (PR). Early toxicities were severe mucositis and erythema with superficial peeling in all patients and a seizure, hypertension, and renal insufficiency followed by veno-occlusive disease in one patient each. Post-transplant treatment included radiotherapy alone (four patients) or plus biological agents (11 patients with neuroblastoma). With a follow-up of 6+ to 32+ (median 11+) months, event-free survivors include 10/11 neuroblastoma patients (first CR), 4/5 brain tumor patients (second PR or CR), 1/3 patients with metastatic Ewing's sarcoma (first or second CR), and a patient transplanted for multiply recurrent immature ovarian teratoma; a patient with desmoplastic small round-cell tumor (second PR) had progressive disease at 8 months. Favorable results for disease control, manageable toxicity, and the antitumor profiles of topotecan, thiotepa, and carboplatin, support use of this three-drug regimen in the treatment of neuroblastoma and brain tumors; applicability to other tumors is still uncertain. Bone Marrow Transplantation (2001) 28, 551-556.
For brain tumors and metastatic solid tumors, supralethal dosing of chemotherapy can overcome obstacles to cure such as chemoresistance and limited drug entry into the central nervous system (CNS). Toxicity risks of this strategy are reduced by the use of cytokines that increase hemopoietic stem cell yield and accelerate hematologic recovery.
When treating metastatic sarcomas, disseminated embryonal tumors of childhood, or brain tumors, we and others have used myeloablative regimens centered on a classical alkylating agent (most commonly melphalan or thiotepa) given with cisplatin or carboplatin. [1] [2] [3] [4] Etoposide is often included for synergistic antitumor effect. However, transplant candidates have often already had considerable exposure to etoposide because this topoisomerase-II inhibitor is a common component of induction regimens. Furthermore, major toxicities of high-dose etoposide -mucositis, hepatotoxicity, leukemogenicity -overlap with those of stem cell toxic alkylators.
These drawbacks to the use of etoposide led us to seek an alternative. We chose topotecan because this topoisomerase-I inhibitor appears to be less affected by the most common multidrug resistance mechanisms, 5, 6 can potentiate antitumor effects of alkylating agents, 7 has good penetration into the CNS, 8 is active against a variety of neoplasms, [9] [10] [11] [12] [13] has myelosuppression as its dose-limiting toxicity, [9] [10] [11] [12] [13] and causes little extramedullary toxicity. [9] [10] [11] [12] [13] [14] [15] We now present our experience with a myeloablative regimen that includes topotecan. Only one other report has appeared on a topotecan-containing myeloablative regimen.
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Patients and methods
The subjects of this report are the first 21 patients who met eligibility requirements for this Memorial Sloan-Kettering Cancer Center phase II/III study: diagnosis of a cancer that had р25% cure rate with conventional therapies; adequate function of kidneys (creatinine clearance у60 ml/min/1.73 m 2 ), heart, and liver (р1.5× normal levels of serum transaminases and bilirubin); and written informed consent in accordance with hospital rules. Eligibility was initially limited to patients with a history of a prior relapse but was extended to patients in first remission once toxicity proved manageable.
The treatment was given over 6 days: topotecan 2 mg/m . The exact daily dose of carboplatin was derived from the pediatric Calvert formula, 17 with a targeted area under the curve of seven mg/ml* min; hence, the daily dose was 7 mg/ml* min × [raw creatinine clearance + (body surface area in square meters ×15)]. However, the daily carboplatin dosage could not exceed 700 mg/m 2 . Autologous bone marrow (BM) or peripheral blood stem cells (PBSCs) were infused on day 0. Granulocyte colony-stimulating factor (G-CSF) 5 g/kg i.v. twice daily was started on day +1 and total parenteral nutrition was started on day +2. Prophylaxis against Pneumocystis carinii was continued until day −3, and prophylactic use of acyclovir was started on day −2 (ie, after completion of all chemotherapy).
Priming with subcutaneous injections of G-CSF (10-15 g/kg per day for 2 to 7 days) preceded BM harvesting and PBSC collections. BM and PBSCs were not treated ('purged') ex vivo. Every 2 to 3 months for 2 years, disease status was assessed, as appropriate for the cancer in question, by BM examinations; computed tomography or magnetic resonance imaging of sites at risk for relapse; scintigraphic studies such as bone scan or metaiodobenzylguanidine scan; and measurement of biochemical tumor markers such as serum alpha-fetoprotein and urine catecholamines. Neuroblastoma patients were assessed by international criteria. 18 Standard criteria were used to classify disease status: complete remission (CR): no evidence of disease; partial remission (PR): Ͼ50% reduction of all disease parameters (except pre-existing lesions by bone scan could be stable); minor response: Ͼ25% but Ͻ50% in all disease parameters, plus no new lesions, or Ͼ50% reduction of any measurable lesion or disease parameter with Ͻ50% reduction in any other; stable disease: Ͻ25% change in all disease parameters and no new lesions; and progressive disease (PD): new lesions or Ͼ25% increase any disease parameter.
Toxicity was graded by criteria of the National Cancer Institute.
Results
Patient characteristics
The 21 patients (12 males; 1 to 29 years old (median, 4)) included 11 with neuroblastoma (Table 1 ) and 10 with other diagnoses including brain tumors (n = 5), Ewing's sarcoma (n = 3), desmoplastic small round cell tumor (DSRCT) (n = 1), and ovarian teratoma (n = 1) ( Table 2) . Of the 13 patients transplanted in first CR, all had received у3 cycles of chemotherapy that included high-dose cyclophosphamide (у4000 mg/m 2 ) and 11 had received two or three cycles that included high-dose cisplatin (200 mg/m 2 ). Comparably aggressive chemotherapy was used in two patients (Nos 18 and 21) with a history of relapse of an extracranial tumor, but one such patient (No. 20) had poor tolerance for chemotherapy because of prior pelvic irradiation. Surgery and radiotherapy were major components of treatment in the patients with brain tumors (all with prior relapses); the three patients with medulloblastoma also received у4 cycles of chemotherapy that included cisplatin.
Toxicity
All patients had grade 4 oropharyngeal mucositis, grade 3-4 skin toxicity with erythema and superficial peeling, and some degree of hearing loss. Intubation was performed only in a patient (No. 15) who had poor brain stem function and had difficulty with upper airway secretions. Patients with normal or near normal hearing at protocol entry developed grade 1 or 2 hearing loss. Patients with significantly impaired hearing at protocol entry were left with grade 3 or 4 deficits.
Seven patients, including one of three who had only one kidney, developed grade 1-2 elevations in serum creatinine. One patient (No. 5) had grade 2 hypertension pretransplant and developed grade 4 hypertension soon after stem-cell rescue, and another patient (No. 10) (who had a history of renal failure after treatment with high-dose cisplatin) developed grade 3 hypertension 2.5 months post transplant. In this last patient, early nephrotoxicity (serum creatinine 1.2-1.7 mg/dl from day −1 to day +15) was followed by veno-occlusive disease of the liver. Otherwise, hepatotoxicity was limited to grade 1-2 increases in serum levels of liver enzymes in 12 patients and grade 3-4 elevations of serum bilirubin in two.
Cardiac function was unaffected although a pericardial effusion was drained on day +28 in a patient (No. 12) who had received 45 Gy craniospinal irradiation 4 months pretransplant.
Neurotoxicity was manifested by a generalized convulsion on day +1 in one patient (No. 7) and a transient organic brain syndrome in two patients (Nos 15 and 21).
Three patients had culture-proven blood-borne bacterial infections (S. epidermidis, Bacillus species, enterococcus). Four patients received dopamine for up to 10 days for unexplained hypotension (no identified infection). Five patients had Clostridium difficile toxin detected in stool. Viral infections included Herpes simplex type 1 (lip), Herpes simplex type 2 (inguinal/vaginal area), rhinovirus-type organism (nasopharynx), cytomegalovirus (antigenemia), and Herpes simplex type 6 variant B (DNA detected in BM during an evaluation for slow engraftment).
The median time to an ANC Ͼ500/l was 10 days in the 14 patients who received PBSCs and 18 days for the seven patients who received BM (Tables 1 and 2 ). Platelets were transfused every 1 to 3 days to a median of 16 days (range, 9-28) post-PBSC infusion and to a median of 25 days (range, 14-86) post BM infusion. Two patients (Nos 7 and 8) received second infusions of BM on day 21 because of slow engraftment. ANC = absolute neutrophil count; BM = bone marrow; CRA = cis-retinoic acid; Cy = cyclophosphamide; Dox = doxorubicin; E = etoposide; GM-CSF = granulocyte-macrophage colony-stimulating factor; mo = months; P = cisplatin or carboplatin; PBSCs = peripheral blood stem cells; PD = progressive disease; RT = radiotherapy; S = surgical excision; V = vincristine. *High-dose cyclophosphamide 140 mg/kg (ෂ4200 mg/m 2 ) or cisplatin 200 mg/m 2 . Table 1 . ActD = dactinomycin; Bleo = bleomycin; GBM = glioblastoma multiforme; I = ifosfamide; Medullo = medulloblastoma; Topo = topotecan. *High-dose cyclophosphamide у4000 mg/m 2 or cisplatin 200 mg/m 2 .
Outcome
The 11 patients with poor-risk neuroblastoma (eight stage 4, three stage 3 with amplified MYCN) were transplanted in first CR: 10 remain in CR at 6+ to 16+ (median 9+) months, and one had a widespread relapse at 3 months (Table 1) . Post-transplant treatments for further consolidation of CR included: 21 Gy local radiotherapy, as described, 19 to the primary site and to previous sites of bulky metastatic deposits; immunotherapy with the anti-G D2 3F8 monoclonal antibody and granulocyte-macrophage colony-stimulating factor; 20 and cis-retinoic acid.
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Each patient treated for a brain tumor had a history of a prior relapse. Both patients with high-grade glial tumors were transplanted in second PR: one relapsed at 7 months and one remains progression-free at 17+ months. The three patients with medulloblastoma were transplanted in second CR and remain progression-free at 9+, 12+ and 26+ months ( Table 2) .
Of three patients with Ewing's sarcoma (Table 2) , two had metastatic disease at diagnosis (lungs, bone, and BM in patient No. 17, lungs in patient No. 19) and were transplanted in first CR, but relapsed 4-5 months later. The third patient (No. 18) with Ewing's sarcoma was transplanted after achieving CR of a distant relapse (kidney, retroperitoneal nodes) that occurred 5 years after therapy for a thoracic paraspinal tumor; she remains in second CR 32+ months post transplant.
Patient No. 20 was transplanted in CR from a multiply recurrent ovarian teratoma (high-grade disease based on the extent of the immature neuroectodermal component) which, at the time of the immediately preceding relapse, extensively involved abdominal organs (Table 2 ). This patient continues in CR 24+ months post transplant.
Patient No. 21 was transplanted after achieving PR of recurrent DSRCT (Table 2) . Residual adenopathy was unaffected by myeloablative therapy and enlarged at 8 months.
Discussion
Patients became candidates for this protocol only when they had derived maximal benefit from, or their cancers had demonstrated sensitivity to, chemotherapy that included nonmyeloablative alkylators such as cyclophosphamide or ifosfamide, antibiotics such as doxorubicin or dactinomycin, and plant alkaloids such as vincristine or etoposide. Reasons for treatment intensification in such patients using thiotepa, carboplatin, and topotecan included the steep dose-response antitumor effect of alkylators, 21, 22 evidence that alkylators are non-crossresistant, 22 the enhancing effect of topotecan on alkylator cytotoxicity, 7 and the activity of each agent against a broad range of cancers, including brain tumors. [9] [10] [11] [12] [13] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Toxicity was severe but manageable. Assessment of antitumor efficacy was limited by CR status at study entry of most patients, short follow-up, post-transplant use of biological therapies in neuroblastoma patients, and the small number of patients with other tumors.
Despite the use of all three agents together, we retained the dosing identified in phase I-II single-agent studies as safe and effective: thiotepa achieved significantly better results at у900 mg/m 2 and dose-limiting CNS toxicity emerged at 1125 mg/m 2 ; carboplatin proved safe in dosages up to 2000 mg/m 2 and had considerable antitumor effect at у1200 mg/m 2 ; and topotecan 10 mg/m 2 divided over 5 days became a commonly used single-agent treatment for relapsed or refractory solid tumors because of impressive antitumor activity and insignificant toxicity. 11, 13, 23, 27, 32 Preclinical studies support combined use of topotecan with alkylators. 7 However, when given with cyclophosphamide or cisplatin in conventional treatments, [33] [34] [35] [36] [37] topotecan has been dosed at 1 to 6 mg/m 2 -well below the singleagent maximally-tolerated dose of 10-12 mg/m 2 .
11,13
Incorporating topotecan into a myeloablative regimen abrogates the need for dose reduction.
We adopted the widespread practice of administering thiotepa and carboplatin in divided doses over several days. We purposely chose to complete the 3 days of thiotepa before the 3 days of carboplatin, and to complete the 5 days of topotecan before the last dose of carboplatin. We rejected the alternative of starting cytoreduction with carboplatin because of concerns that nephrotoxic effects of that agent might alter the pharmacokinetics of thiotepa, topotecan, and/or their cytotoxic metabolites, and thereby enhance toxicity. The validity of our concerns was subsequently supported by results of a phase I dose-escalation study of topotecan combined with thiotepa and carboplatin. 16 In that study, thiotepa and carboplatin were dosed as in our protocol, but the 3 days of carboplatin preceded the 3 days of thiotepa, and the topotecan was given from the second to the sixth and last day of the cytoreduction rather than from the first to the fifth day (as in our protocol). Excessive mucosal toxicity, which correlated with increased exposure to topotecan documented in pharmacokinetic studies, led to a recommendation of 1.5 mg/m 2 /day × 5 (total, 7.5 mg/m 2 ) as the maximally tolerated dose of topotecan in that setting. The data pointed to an interactive effect between carboplatin and/or thiotepa and clearance of topotecan. In our patients, the alternative drug scheduling and higher topotecan dosing (10 mg/m 2 ) caused mucositis that was severe but manageable, similar to the toxicity caused by our prior myeloablative regimens 1,2 which included the same thiotepa dosing plus etoposide 750-900 mg/m 2 . The relapse-free results to date are consistent with the previously reported 23, 25, 28, 29, 38 efficacy of thiotepa and carboplatin against brain tumors and poor-prognosis germ cell tumors; the addition of topotecan may enhance efficacy. A beneficial role for this or any other myeloablative regimen in the treatment of metastatic sarcomas is uncertain. 4, 39 All three agents are active against neuroblastoma 10, 23, 30 and their use together may help overcome two vexing problems of that embryonal neoplasm -viz., minimal residual disease 3, 20 and CNS relapse. 40 Occult residual neuroblastoma has long been a target of myeloablative regimens and its control may be improved with the addition of biological therapies, such as the differentiation-inducer cis-retinoic acid 3 and immunotherapy with anti-G D2 monoclonal antibodies. 20 However, evidence of efficacy against CNS disease is lacking for cis-retinoic acid and it is unlikely that monoclonal antibodies gain entry into the CNS at allhence, the possible advantage in the treatment of neuroblastoma of a myeloablative regimen comprised of agents that cross the blood-brain barrier, over widely used regimens centered on melphalan which has poor CNS penetration. 31 In conclusion, favorable preliminary results for disease control, manageable toxicity, and the antitumor profiles of topotecan, thiotepa and carboplatin, support the use of this three-drug regimen in the treatment of neuroblastoma and brain tumors; applicability to other tumors is still uncertain.
